Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Study of Ivarmacitinib in Severe Alopecia Areata
ChiCTR2600130424Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivarmacitinib in alopecia areata, sponsored by China-Japan Friendship Hospital. Primary endpoint: Proportion of participants with SALT <= 20 at Week 24. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on ChiCTR2600130424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130424.